When people swallow a pill or apply an ointment prescribed by their doctor, they rarely stop to wonder whether the medicine in their hand is genuine, safe, and effective. There is an unspoken trust that what is being sold in pharmacies or hospitals has passed through rigorous quality checks before reaching the patient. But recent findings from the Central Drugs Standard Control Organization (CDSCO) have once again shaken that trust and raised serious concerns about drug safety in India.

CDSCO laboratories, along with state-run testing facilities, identified as many as 94 batches of medicines and medical products that failed to meet prescribed pharmacopeial and safety standards. These were officially labelled “Not of Standard Quality” or NSQ, a term that carries deep implications for the pharmaceutical industry, regulatory authorities, and most importantly, millions of patients who consume these drugs every single day. The revelation is a reminder that lapses in drug quality are not just regulatory failures but matters of life and death.

The range of products flagged is wide and worrying. Among them were commonly used antibiotics, drugs for heart conditions, gastrointestinal medicines, hormonal injections, pain relief formulations, ophthalmic drops, multivitamins, and even some cosmetic items. To name a few, Paracetamol tablets manufactured by Savya Pharmaceuticals were part of the list, which is alarming given how widely paracetamol is used in India as a fever and pain reliever. Tobramycin eye drops produced by Agron Remedies, Amikacin sulphate injections from Zee Laboratories, Tacrolimus ointment by Zoic Biotech, Rabeprazole tablets from Morepen Laboratories, and Metronidazole tablets from Bochem Healthcare also failed to meet standards. Even cosmetic products such as the Fast Color Mehendi cones were declared non-compliant due to the presence of prohibited chemical compounds like Picramic Acid and PPD, which can cause skin reactions and other health complications.

The reasons for these failures varied, but each pointed towards gaps in manufacturing processes and oversight. Some batches did not pass basic assay tests, meaning the quantity of active pharmaceutical ingredient was either too low or too high, raising questions about efficacy and safety. Others showed problems with dissolution and disintegration, meaning the drug would not release in the body as intended, reducing its therapeutic effect. More serious lapses included sterility issues in injectable medicines, particulate contamination, deviations in pH levels, and even incorrect or misleading labels on products. Each of these flaws is not just a technical error; it has the potential to harm patients in real-world use.

The testing process was thorough and spread across different regions of the country, underlining that the problem is not limited to one corner of India. Samples were analyzed in CDSCO’s central laboratories located in Kolkata and Chandigarh, along with state-run facilities in Jaipur, Baddi, Guwahati, Telangana, Karnataka, Puducherry, and Jammu & Kashmir. After rigorous testing, all these laboratories concluded that the flagged products did not comply with the Indian Pharmacopoeia standards.

Under Indian law, particularly the Drugs and Cosmetics Act of 1940, a drug is classified as “Not of Standard Quality” when it does not conform to the quality benchmarks laid down in the official pharmacopeia. Section 16(1)(a) of the Act defines this clearly, emphasizing that any drug must meet the standards listed in the Second Schedule of the Act to be considered safe and fit for consumption. A failure to meet these standards is not a minor regulatory deviation but a violation that directly affects patient safety.

The presence of NSQ drugs in the market has broader implications than many realize. For one, it shakes public confidence in the pharmaceutical system. India is often referred to as the “pharmacy of the world,” exporting billions of dollars worth of medicines to more than 200 countries. If quality lapses at home continue to make headlines, it not only jeopardizes domestic trust but also damages India’s international credibility as a reliable drug supplier.

Antibiotics that do not contain the correct dosage of active ingredient can contribute to antimicrobial resistance, one of the gravest health challenges of our time. Injections that are not sterile can cause infections instead of curing them. Eye drops contaminated with particulate matter can permanently damage vision. Even seemingly harmless products like hair dye cones or herbal mehendi, when laced with dangerous chemicals, can cause allergic reactions, skin burns, or systemic toxicity. These risks highlight that drug quality is not just about numbers in a lab report but about safeguarding human lives.

The pharmaceutical companies whose products were flagged may present arguments that a failed batch is a rare occurrence or that issues were limited to certain lots. While such defenses are common, the sheer number of 94 failed batches in a single month raises deeper questions. Is there a larger systemic issue in quality control across manufacturing plants? Are regulatory inspections and audits stringent enough to prevent such lapses before medicines reach the market? And most critically, why do these repeated lapses keep surfacing despite India’s robust regulatory framework?

It is also worth noting that these failures are not limited to small, obscure manufacturers. Some of the names in the list are well-known players in the industry with decades of presence. When established companies appear alongside lesser-known firms in such reports, it suggests that gaps in compliance and quality assurance are more widespread than assumed.

For regulators like CDSCO, these findings serve as both validation and challenge. On one hand, it proves that the surveillance mechanisms are working and that poor-quality drugs are being identified. On the other hand, it reveals how many such drugs have already entered circulation before detection, putting thousands of patients at risk. The role of state drug control authorities becomes equally crucial here, since enforcement of recalls and penalties must be swift and uncompromising to protect public health.

Looking at global practices, countries with advanced regulatory systems like the United States and those in the European Union have strict recall processes where companies are legally compelled to withdraw non-compliant batches quickly. Public notices are issued widely, and penalties are severe enough to deter repeated violations. India, with its massive pharmaceutical industry, needs to match or even exceed such global benchmarks to ensure its medicines are trusted everywhere.

The issue also ties into the larger conversation about patient safety in India. Over the years, there have been multiple reports of contaminated cough syrups, substandard injections, and adulterated formulations causing harm and even deaths, especially among children. Each incident leads to temporary outrage, stricter circulars, and promises of reform. But without consistent enforcement, the cycle repeats itself. This latest CDSCO report is a fresh reminder that drug safety must remain a continuous and uncompromising priority.

What makes the situation more urgent is the sheer scale of India’s medicine consumption. With a population of over 1.4 billion, even a small fraction of substandard drugs can affect millions. Hospitals, clinics, and pharmacies rely heavily on timely supplies of affordable medicines, and patients rarely have the means to verify the quality of what they receive. The responsibility therefore lies squarely with manufacturers and regulators to ensure that every pill, every drop, and every injection meets the highest standard of quality.

The road ahead requires multiple layers of action. Pharmaceutical companies must strengthen their internal quality assurance mechanisms, investing in better manufacturing practices, advanced technology, and routine audits. Regulators must enforce compliance with zero tolerance, ensuring that companies cannot escape accountability through legal loopholes or influence. Awareness campaigns can also empower patients and doctors to report adverse drug reactions or suspected poor-quality products, creating a culture of vigilance that complements regulatory oversight.

The story is not one that can fade away with time. It must remain a turning point, pushing every stakeholder in the pharmaceutical chain to rise above complacency. Because in the end, the real measure of a nation’s healthcare system is not how many medicines it produces, but how safe, reliable, and effective those medicines are when they reach the people who depend on them.